Disease · MONDO_0005861
multidrug-resistant tuberculosis
6 sourcesdiseases-2026-09-18-0.1.0
Cite this record
ConductScience Library. multidrug-resistant tuberculosis. Diseases, record MONDO_0005861. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0005861
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
Drugs19
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| BEDAQUILINE | CHEMBL376488 | Small molecule | Approval | EMA Human Drugs | 10 | 9 | 9 | Drugs and targets |
| DELAMANID | CHEMBL218650 | Small molecule | Approval | EMA Human Drugs | 7 | 6 | 6 | Drugs and targets |
| PRETOMANID | CHEMBL227875 | Small molecule | Approval | EMA Human Drugs | 5 | 4 | 4 | Drugs and targets |
| LINEZOLID | CHEMBL126 | Small molecule | Phase 3 | ClinicalTrials.gov | 11 | 11 | 11 | Drugs and targets |
| CLOFAZIMINE | CHEMBL1292 | Small molecule | Phase 3 | ClinicalTrials.gov | 8 | 8 | 8 | Drugs and targets |
| PYRAZINAMIDE | CHEMBL614 | Small molecule | Phase 3 | ClinicalTrials.gov | 8 | 8 | 8 | Drugs and targets |
| MOXIFLOXACIN | CHEMBL32 | Small molecule | Phase 3 | ClinicalTrials.gov | 7 | 7 | 7 | Drugs and targets |
| LEVOFLOXACIN | CHEMBL5315124 | Small molecule | Phase 3 | ClinicalTrials.gov | 5 | 5 | 5 | Drugs and targets |
| AMIKACIN | CHEMBL177 | Small molecule | Phase 2/3 | ClinicalTrials.gov | 3 | 3 | 3 | Drugs and targets |
| KANAMYCIN | CHEMBL1384 | Small molecule | Phase 2/3 | ClinicalTrials.gov | 3 | 3 | 3 | Drugs and targets |
1 to 10 of 19
See all 19 drugsTargets3
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| IL2RA | Interleukin-2 receptor | 1 | Interleukin-2 receptor agonist | Phase 2/3 | https://conductscience.org/library/genes/3559 | Drugs and targets |
| IL2RB | Interleukin-2 receptor | 1 | Interleukin-2 receptor agonist | Phase 2/3 | https://conductscience.org/library/genes/3560 | Drugs and targets |
| IL2RG | Interleukin-2 receptor | 1 | Interleukin-2 receptor agonist | Phase 2/3 | https://conductscience.org/library/genes/3561 | Drugs and targets |
Trials16
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01424670 | Safety and Efficacy Trial of Delamanid for 6 Months in Participants With Multidrug-resistant Tuberculosis | Phase 3 | 511 | 2019-05-15 | Multidrug-resistant Tuberculosis | DELAMANID | Its record names the disease | ClinicalTrials.gov |
| NCT02619994 | Treatment Shortening of MDR-TB Using Existing and New Drugs | Phase 2 | 214 | 2025-01-03 | Tuberculosis, Multidrug-Resistant | DELAMANID, LEVOFLOXACIN, LINEZOLID, PYRAZINAMIDE | Its record names the disease | ClinicalTrials.gov |
| NCT00449644 | TMC207-TiDP13-C208: Anti-bacterial Activity, Safety, and Tolerability of TMC207 in Participants With Multi-drug Resistant Mycobacterium Tuberculosis (MDR-TB). | Phase 2 | 208 | 2013-06-25 | Tuberculosis | BEDAQUILINE | Its record names the disease | ClinicalTrials.gov |
| NCT02754765 | Evaluating Newly Approved Drugs for Multidrug-resistant TB | Phase 3 | 754 | Tuberculosis, Multidrug-Resistant, Infection, Bacterial, Pulmonary Tuberculoses | BEDAQUILINE, CLOFAZIMINE, DELAMANID, LEVOFLOXACIN, LINEZOLID, MOXIFLOXACIN, PYRAZINAMIDE | Its record names the disease | ClinicalTrials.gov | |
| NCT04421495 | Safety and Effectiveness of Delamanid-containing Regimen for MDR-TB Patients in China | Phase 4 | 608 | Multidrug Resistant Tuberculosis | DELAMANID | Its record names the disease | ClinicalTrials.gov | |
| NCT02589782 | Pragmatic Clinical Trial for a More Effective Concise and Less Toxic MDR-TB Treatment Regimen(s) | Phase 2/3 | 552 | Tuberculosis, Multidrug-Resistant, Extensively Drug-Resistant Tuberculosis, Tuberculosis, Pulmonary | BEDAQUILINE, CLOFAZIMINE, LINEZOLID, MOXIFLOXACIN, PRETOMANID | Its record names the disease | ClinicalTrials.gov | |
| NCT03069534 | Study of Adjunctive Recombinant Human Interleukin-2 Therapy in Patients With MDR-TB | Phase 2/3 | 500 | MDR TB | ALDESLEUKIN, AMIKACIN, AMINOSALICYLIC ACID, CAPREOMYCIN, KANAMYCIN, LEVOFLOXACIN, PROTIONAMIDE, PYRAZINAMIDE | Its record names the disease | ClinicalTrials.gov | |
| NCT03604848 | NGS-Guided(G) Regimens(R) of Anti-tuberculosis(A) Drugs for the Control(C) and Eradication(E) of MDR-TB | Not applicable | 488 | Multidrug Resistant Tuberculosis | AMIKACIN, CLOFAZIMINE, CYCLOSERINE, ETHAMBUTOL, LINEZOLID, MOXIFLOXACIN, PROTIONAMIDE, PYRAZINAMIDE | Its record names the disease | ClinicalTrials.gov | |
| NCT03896685 | Evaluating Newly Approved Drugs in Combination Regimens for Multidrug-Resistant TB With Fluoroquinolone Resistance (endTB-Q) | Phase 3 | 323 | Tuberculosis, Multidrug-Resistant, Tuberculosis, Pulmonary Tuberculoses, Mycobacterial Infections, Bacterial Infections, Gram-Positive Bacterial Infections | BEDAQUILINE, CLOFAZIMINE, DELAMANID, LINEZOLID | Its record names the disease | ClinicalTrials.gov | |
| NCT07126639 | A Study on the Short-course Treatment Regimen Containing Pretomanid for Drug-resistant Tuberculosis | Not applicable | 200 | Efficacy and Safety | BEDAQUILINE, LINEZOLID, MOXIFLOXACIN, PRETOMANID | Its record names the disease | ClinicalTrials.gov |
1 to 10 of 16
See all 16 trialsComparisons in its trials13
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Delamanid + OBR vs Placebo + OBR: Number of Participants Who Developed Resistance To Delamanid | 3 of 341 | 0 of 170 | 511 | NCT01424670 | Trial comparisons |
| Delamanid + OBR vs Placebo + OBR: deaths from any cause | 18 of 341 | 8 of 170 | 511 | NCT01424670 | Trial comparisons |
| Delamanid + OBR vs Placebo + OBR: serious adverse events | 89 of 341 | 47 of 170 | 511 | NCT01424670 | Trial comparisons |
| Experimental Arm vs Control Arm: Proportion of Death Between the Control and Investigational Arms | 5 of 79 | 2 of 89 | 168 | NCT02619994 | Trial comparisons |
| Experimental Arm vs Control Arm: deaths from any cause | 5 of 79 | 2 of 89 | 168 | NCT02619994 | Trial comparisons |
| Experimental Arm vs Control Arm: serious adverse events | 20 of 79 | 19 of 89 | 168 | NCT02619994 | Trial comparisons |
| Experimental Arm vs Control Arm: Treatment Success at the End of Treatment | 61 of 78 | 64 of 89 | 167 | NCT02619994 | Trial comparisons |
| Experimental Arm vs Control Arm: Proportion of Reverting to Positive Sputum Culture After the End of Treatment | 1 of 72 | 0 of 85 | 157 | NCT02619994 | Trial comparisons |
| Experimental Arm vs Control Arm: Treatment Success Rate | 54 of 72 | 60 of 85 | 157 | NCT02619994 | Trial comparisons |
| Experimental Arm vs Control Arm: Sputum Culture Conversion Proportion | 39 of 49 | 45 of 52 | 101 | NCT02619994 | Trial comparisons |
1 to 10 of 13
See all 13 comparisons in its trialsPapers from its trials23
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
| PMID | Listed as | Trials listing it | Source |
|---|---|---|---|
| 19494215 | RESULT | 1 | PubMed |
| 41419836 | DERIVED | 1 | PubMed |
| 41090140 | DERIVED | 1 | PubMed |
| 40683298 | DERIVED | 1 | PubMed |
| 39879593 | DERIVED | 1 | PubMed |
| 38842323 | DERIVED | 1 | PubMed |
| 38037119 | DERIVED | 1 | PubMed |
| 37980911 | DERIVED | 1 | PubMed |
| 37035978 | DERIVED | 1 | PubMed |
| 36546625 | DERIVED | 1 | PubMed |
1 to 10 of 23
See all 23 papers from its trialsData dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0005861
GET https://conductscience.org/api/diseases/v1/MONDO_0005861/papers?page=2